The Omniose bioconjugate vaccine platform enables the precise enzymatic attachment of virtually any bacterial polysaccharide (sugar) antigen to engineered carrier proteins within a single E. coli cell. Hence the name Omniose, “all sugars”. This allows the already established benefits of bioconjugation to be applied to a broader range of bacterial vaccines. Bioconjugation is a much simpler process than conventional chemical conjugation methods and has the potential to produce higher quality vaccines. However, the enzymes used for bioconjugation thus far could only address a limited range of bacterial targets. Omniose is breaking through this barrier.
